Cleo Diagnostics Receives Positive FDA Feedback for Ovarian Cancer Blood Test, Advancing Toward US Approval
Key Insights
Australian biotech Cleo Diagnostics (search) received constructive FDA feedback during its second pre-submission meeting, reinforcing confidence in its 510(k) regulatory strategy for an ovarian cancer (search) triage test.
The company's blood-based diagnostic utilizes the patented CXCL10 (search) biomarker, which is produced at high levels by ovarian cancers but largely absent in non-malignant disease.
FDA guidance addressed critical technical elements including clinical trial design and sample stability, positioning Cleo to proceed with greater confidence toward its 2024 submission.
Australian biotech Cleo Diagnostics (search) has advanced significantly in its regulatory journey following positive feedback from the US Food and Drug Administration during its second pre-submission meeting for an innovative ovarian cancer (search) blood test. The company's Quality and Regulatory Manager, Emma Lester, attended the meeting in person at the FDA's headquarters in Silver Spring, Maryland, where discussions focused on critical technical elements for the company's US regulatory strategy.
FDA Guidance Reinforces Regulatory Strategy
The FDA's feedback addressed key aspects of Cleo's development program, including clinical trial design, sample stability, use of biobank samples, clinical specificity, and intended use within surgical workflows. According to the company, the agency's guidance was "highly constructive" and reinforced confidence that its pivotal clinical trial design and broader regulatory approach align with FDA expectations.
The positive feedback validates Cleo's 510(k) strategy, an expedited approval pathway for technologies that demonstrate equivalence to existing devices. By reducing regulatory risk, the company said it is positioned to proceed with greater confidence as it prepares its submission next year.
"This second round of positive feedback from the FDA marks another important milestone in our regulatory journey," said Chief Executive Officer Dr Richard Allman. "The FDA's guidance enables us to strengthen our trial design and move forward with greater confidence in our 510(k) strategy. It supports our approach and underscores the opportunity Cleo has to deliver a clinically meaningful and accessible solution to support more appropriate surgical triage for ovarian cancer (search)."
CXCL10 Biomarker Technology
Cleo's diagnostic platform centers on a patented biomarker, CXCL10 (search), which is produced early and at high levels by ovarian cancers but largely absent in non-malignant disease. The test is designed to distinguish benign from malignant growths and is compatible with existing diagnostic laboratory equipment worldwide.
The technology is backed by over a decade of research at the Hudson Institute of Medical Research, where Cleo holds an exclusive worldwide license to commercialize the intellectual property. The test has already been validated in clinical studies involving more than 500 patients.
Addressing Critical Medical Need
The clinical need for improved ovarian cancer (search) detection is urgent, as the disease remains one of the deadliest gynecological malignancies. Earlier detection could significantly shift survivability outcomes, according to the company.
Cleo's modular execution strategy aims to expand the test beyond surgical triage to other markets, including recurrence monitoring, high-risk populations, and eventually early-stage screening. The FDA guidance allows the company to enhance its clinical trial design and strengthen data collection processes for a high-quality submission, positioning it strongly for its upcoming US commercial launch.